Items Tagged with 'Pfizer'

ARTICLES

Purchase ceiling raised for two stock picks.

Updates for May 2013: Purchase Price Raised for Pfizer and J&J

In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.
Read More
PFE Complete $11.85 billion Sale

Pfizer Completes Sale of Nutrition Business to Nestlé

On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.


Read More
PFE Announces Revenues of $14.0 billion

Pfizer Reports Third-Quarter 2012 Results

On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.


Read More
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion

Pfizer Second Quarter Financials Released

On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.


Read More
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.


Read More
PFE Reports 7% Revenue Decrease

Pfizer Financials Announced

On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.


Read More
PFE to Divest Nutrition Business

Pfizer and Nestle Nutrition Business Agreement Announced

On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.


Read More
Pfizer Buys Vitamin C Icon

Pfizer Acquisition Announced

On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....


Read More

Pfizer Recall Announced

On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.


Read More

Pfizer FDA Approval Received

On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.


Read More

Your Financial Security is Serious Business...

so why should you trust The Turnaround Letter?

  • Ranked #1 for 15-Yr. Annualized Returns: Turnaround Letter's 13.2% vs. S&P's 2.2%
  • 28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
  • Diverse Monthly Stock Picks Personally Selected by George Putnam

Distressed Investing Blog

Distressed Investing Blog

Looking for a Year-End Bounce: Stock Profit from Artificial Selling Pressures

Looking to cash in on timely tax loss selling and portfolio window dressing? These 10 year-end bounce stock picks represent the worst performers in the S&P 500 during calendar 2014, adjusted somewhat so that there is good diversification by industry group. Read More.

Sample Issue

TL Spotlight

George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary long-term stock profit ever since.

 

In fact, 12 of 2014's 13 closed-out purchase recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average return for 2014's stock picks is +82%:

 

2014 Closed Out Purchase Recommendations

Value Stock Picks

* Calculation includes dividends and price changes between purchase recommendation and current price.

 

Learn more.